#### **Technical Data Sheet**

# InVivoMAb anti-mouse CTLA-4 (CD152)



## **Lot Specific Information**

Lot Number:Lot Specific\*Volume:Lot Specific\*

Concentration: Lot Specific\* (generally 4 to 11 mg/ml) \*

Total Protein: Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

#### **Product Information**

Catalog Number:BE0032Clone:UC10-4F10-11Isotype:Armenian Hamster IgG

Recommended Isotype Control(s): InVivoMAb polyclonal Armenian hamster IgG

Recommended Dilution Buffer: InVivoPure pH 6.5 Dilution Buffer

Immunogen: Mouse CTLA-4 IgG2a fusion protein

in vivo CTLA-4 neutralization in vitro CTLA-4 neutralization

Reported Applications:

### Reported Applications:

### Reported Applications:

### Reported Applications:

#### Reported Applications:

Western blot

Formulation: PBS, pH 6.5
Contains no stabilizers or preservatives

process and the state of process and the state of the sta

**Endotoxin:** <2ΕU/mg (<0.002ΕU/μg)

Determined by LAL gel clotting assay

Purity: >95%

Determined by SDS-PAGE

Sterility: 0.2 µM filtered

**Production:** Purified from tissue culture supernatant in an animal free facility

Purification:Protein GRRID:AB\_1107598Molecular Weight:150 kDa

#### **Description**

The UC10-4F10-11 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the Ct/a4 gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The UC10-4F10-11 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.

### **Shelf-life and Storage**

Store at the stock concentration at  $4\,^{\circ}\text{C}.$  Do not freeze.

## **Protocol Information**

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

## **Application References**

For a complete list of references, visit https://bxcell.com/product/m-cd152-m-ctla-4-2/#references or scan the QR code below.

### Bio X Cell, Inc.

bxcell.com 1.866.787.3444


customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.



## **Binding Validation**

Western blot data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, email technicalservice@bxcell.com.



Lane 1:1 µg reduced purified mouse

CTLA-4 with histidine tag

Lane 2: 0.5 µg reduced purified mouse

CTLA-4 with histidine tag

Primary: anti-mouse CTLA-4 antibody

(UC10-4F10-11) at 15 μg/ml

Secondary: HRP labeled rabbit anti-

hamster at 1:1000 dilution

Predicted band size: 25-30 kDa

Bio X Cell, Inc.

bxcell.com 1.866.787.3444